首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Novel benzamido derivatives as PTP1B inhibitors with anti-hyperglycemic and lipid-lowering efficacy
【2h】

Novel benzamido derivatives as PTP1B inhibitors with anti-hyperglycemic and lipid-lowering efficacy

机译:新型苯甲酰胺衍生物作为PTP1B抑制剂具有抗高血糖和降脂功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Based on a non-competitive and selective PTP1B inhibitor reported by us previously, thirty-nine benzamido derivatives were designed and synthesized as novel PTP1B inhibitors. Among them, twelve compounds exhibited IC50 values at micromolar level against human recombinant PTP1B, and most of them exhibited significant selectivity to PTP1B over TC-PTP and CD45. Further evaluation of the most potent compound >27 on high-fat diet (HFD)-induced insulin-resistant (IR) obese mice indicated that >27 could modulate glucose metabolism and ameliorate dyslipidemia simultaneously.
机译:基于我们先前报道的非竞争性和选择性PTP1B抑制剂,设计并合成了39种苯甲酰胺衍生物作为新型PTP1B抑制剂。其中,十二种化合物对人重组PTP1B表现出微摩尔水平的IC50值,并且大多数相对于TC-PTP和CD45表现出对PTP1B的显着选择性。对高脂饮食(HFD)诱导的胰岛素抵抗(IR)肥胖小鼠中最有效的化合物> 27 的进一步评估表明,> 27 可以调节葡萄糖代谢并改善血脂异常同时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号